Drug Profile

CEQ 508

Alternative Names: CEQ508

Latest Information Update: 03 May 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Marina Biotech
Developer Adhera Therapeutics
Class Antineoplastics; RNA
Mechanism of Action Beta catenin inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Familial adenomatous polyposis
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Familial adenomatous polyposis

Most Recent Events

16 Apr 2019 Discontinued - Phase-I/II for Familial adenomatous polyposis in USA (PO)
08 Sep 2017 Efficacy data from the phase I/II START-FAP trial in Familial adenomatous polyposis presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
10 Jul 2017 The primary endpoint was met in the phase I/II START-FAP trial in Familial adenomatous polyposis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com